{
    "clinical_study": {
        "@rank": "74046", 
        "acronym": "MATEO", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: De-escalation therapy", 
                "arm_group_type": "Experimental", 
                "description": "Patients in Arm A will continue with S-1 de-escalation phase starting at week 13 until disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or lost to follow up whichever occurs first. In patients with drug-related severe toxicity S-1 dose will be adjusted or study treatment will be terminated."
            }, 
            {
                "arm_group_label": "Arm B: Chemotherapy by Investigator's choice", 
                "arm_group_type": "Experimental", 
                "description": "Patients in Arm B will continue to receive the same polychemotherapy as during induction therapy until tumor progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or loss to follow up whichever occurs first."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim is to assess the relative efficacy of S-1 de-escalation therapy vs. continuation of\n      chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in\n      terms of overall survival."
        }, 
        "brief_title": "Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Esophagogastric Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "detailed_description": {
            "textblock": "Open-label, multi-center, controlled, randomized, parallel-group phase II trial in patients\n      with metastatic esophagogastric cancer having received induction chemotherapy.\n\n      Patients will be registered before the initiation of first-line chemotherapy regimen. This\n      12-week induction therapy will consist of one of the following regimens: FLO/mod. FOLFOX-6,\n      Cisplatin/S-1, FLOT or EOX/EOF (see interventions for specification of regimens). Regarding\n      dose adjustments, Investigators should refer to Section 6.3 and to the summary of product\n      characteristics of the chemotherapeutical agents. Patients having finished the preplanned\n      induction therapy without tumor progression (i.e. with complete remission (CR), partial\n      remission (PR) or stable disease (SD) according to Response Evaluation Criteria in Solid\n      Tumors (RECIST) Criteria Version 1.1) at week 12, being able to swallow capsules and having\n      Eastern Cooperative Oncology Group (ECOG) performance score of 0-1 will be randomized in a\n      2:1 ratio to receive Arm A or B.\n\n      In Arm A patients will continue with S-1 de-escalation phase starting at week 13 until\n      disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy,\n      death or lost to follow up whichever occurs first. In patients with drug-related severe\n      toxicity S-1 dose will be adjusted or study treatment will be terminated.\n\n      In Arm B patients will continue to receive the same polychemotherapy as during induction\n      therapy until tumor progression, toxicities requiring discontinuation, withdrawal of\n      consent, pregnancy, death or loss to follow up whichever occurs first."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consent incl. participation in translational research\n\n          2. Male or female patient 18 years or older\n\n          3. Histologically confirmed metastatic or locally advanced unresectable gastric\n             adenocarcinoma or adenocarcinoma of the esophagus or the esophagogastric junction\n             (Her-2/neu negative or with unknown Her-2/neu status)\n\n          4. Measurable disease as per RECIST 1.1 criteria\n\n          5. Adjuvant/neoadjuvant or perioperative chemotherapy or (chemo-)radiotherapy must have\n             been finished at least 6 months before study entry\n\n          6. No previous systemic treatment (i.e.chemotherapy) for metastatic disease\n\n          7. ECOG Performance Score 0-1 (Karnofsky Performance status >= 80%)\n\n          8. Ability for oral intake of the study drug, patients with tumor-related problems with\n             oral intake might be registered if the symptom is expected to be improved during\n             induction therapy (e.g. due to a tumor stenosis)\n\n          9. Female patient of childbearing potential (i.e. did not undergo surgical sterilization\n             - hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and is not\n             post-menopausal for at least 24 consecutive months) with a negative pregnancy test\n\n         10. Hematology and biochemistry laboratory results within the limits normally expected\n             for the patient population, defined by the following:\n\n               -  Absolute neutrophil count \u2265 1500/\u03bcl\n\n               -  Platelet count \u2265 100000/\u03bcl\n\n               -  Leukocyte count > 3000/\u03bcl\n\n               -  Hemoglobin \u2265 9 g/dL or 5.59 mmol/l, previous transfusions (>3 days) of\n                  erythrocytes are allowed\n\n               -  Total bilirubin \u2264 1.5 times the upper limit of normal (ULN), in patients with\n                  known Meulengracht syndrome \u2264 3x ULN\n\n               -  Aspartate aminotransferase (AST) \u2264 3x ULN in absence of liver metastases, or \u2264\n                  5x ULN in presence of liver metastases\n\n               -  Alanine aminotransferase (ALT) \u2264 3x ULN in absence of liver metastases, or \u2264 5x\n                  ULN in presence of liver metastases\n\n               -  Creatinine clearance \u226530 mL/min according to Cockcroft-Gault formula\n\n        Exclusion Criteria:\n\n          1. Previous major surgery within the last 28 days before the start of the induction\n             treatment. The implantation of a central venous access (e.g. port-a cath system) is\n             allowed.\n\n          2. History of other malignant tumors within the last 5 years, except basal cell\n             carcinoma or curatively excised cervical carcinoma in situ\n\n          3. Known brain metastases\n\n          4. Concurrent radiotherapy involving target lesions used for this study. Concurrent\n             palliative radiation for non-target lesions is allowed if other target lesions are\n             available outside the involved field; previous radiotherapy including target lesions\n             must have been finished at least 28 days before start of induction treatment.\n\n          5. Previous systemic treatment (i.e. chemotherapy) for metastatic disease\n\n          6. Known active Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or documented\n             HIV infection\n\n          7. Serious concomitant disease or medical condition that by judgment of the Investigator\n             renders the patient at high risk of treatment complications\n\n          8. Clinically relevant coronary artery disease (NYHA functional angina classification\n             III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy,\n             history of myocardial infarction in the last 3 months, or high risk of uncontrolled\n             arrhythmia\n\n          9. Female patient pregnant or breast feeding\n\n         10. Female patient of childbearing potential (i.e. did not undergo surgical sterilization\n             - hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and is not\n             post-menopausal for at least 24 consecutive months) not willing to use an adequate\n             method of contraception to avoid pregnancy throughout the study and for up to 26\n             weeks after the end of treatment. Male patient not willing to use an adequate method\n             of contraception to avoid conception throughout the study and for up to 26 weeks\n             after the end of treatment in such a manner that the risk of pregnancy is minimized.\n\n         11. Concurrent treatment with other experimental drugs or participation in another\n             clinical trial with any investigational drug within 60 days prior to start of\n             induction\n\n         12. Chronic diarrhea or short bowel syndrome\n\n         13. Known hypersensitivity to S-1, other fluoropyrimidines or platinum compounds.\n             Contraindication to receive S-1 as per current Summary of Product Characteristics.\n             Known Dihydropyrimidine dehydrogenase (DPD) deficiency\n\n         14. Grade \u22652 peripheral neuropathy\n\n         15. Known drug abuse/alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128243", 
            "org_study_id": "AIO-YMO-0111", 
            "secondary_id": "2013-002742-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: De-escalation therapy", 
                "description": "S-1 30 mg/m\u00b2 bid d1-14 q21d", 
                "intervention_name": "S-1 de-escalation", 
                "intervention_type": "Drug", 
                "other_name": "Teysuno"
            }, 
            {
                "arm_group_label": "Arm B: Chemotherapy by Investigator's choice", 
                "description": "Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.\nTwo-Drug combinations:\nFLO / mod. FOLFOX-6 Cisplatin, S-1\nThree-drug combinations:\nEOX/EOF FLOT", 
                "intervention_name": "Chemotherapy by Investigator's choice", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FLO regimen", 
                    "- Oxaliplatin 85 mg/m\u00b2", 
                    "- Leucovorin 200 mg/m\u00b2", 
                    "- 5-Fluorouracil 2600 mg/m\u00b2", 
                    "mod. FOLFOX-6 regimen", 
                    "- Leucovorin 400 mg/m\u00b2", 
                    "- 5-Fluorouracil 400 mg/m\u00b2", 
                    "- 5-Fluorouracil 2400 mg/m\u00b2", 
                    "Cisplatin / S-1", 
                    "- Cisplatin 75 mg/m\u00b2", 
                    "- S-1 25mg/m\u00b2", 
                    "EOX/EOF", 
                    "- Epirubicin 50 mg/m\u00b2", 
                    "- Oxaliplatin 130 mg/m\u00b2", 
                    "- Capecitabine 625 mg/m\u00b2", 
                    "FLOT", 
                    "- Docetaxel 50 mg/m\u00b2", 
                    "- Leucovorin 200 mg/mg\u00b2"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Cisplatin", 
                "Fluorouracil", 
                "Leucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 30, 2014", 
        "link": {
            "description": "Working Group for Medical Oncology (AIO) from the German Cancer Society (DKG)", 
            "url": "http://www.aio-portal.de"
        }, 
        "location": {
            "contact": {
                "email": "GeorgMartin.Haag@med.uni-heidelberg.de", 
                "last_name": "Georg Martin Haag, Dr.", 
                "phone": "+49-6221", 
                "phone_ext": "5637630"
            }, 
            "facility": {
                "address": {
                    "city": "Heidelberg", 
                    "country": "Germany", 
                    "state": "Baden-W\u00fcrttemberg", 
                    "zip": "69120"
                }, 
                "name": "NCT-Med. Onkologie"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer", 
        "other_outcome": [
            {
                "description": "Explorative descriptive statistical methods will be applied to describe the results of the Nutritional Risk Screening stratified by visit and treatment arm.", 
                "measure": "Malnutrition", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "For exploratory purposes, the overall survival experience of non-randomized patients will be considered. The survival time is defined as the time length between start of induction therapy and the date of death from any cause or the date of last follow-up in case of no documentation of death.", 
                "measure": "Overall Survival of non-randomized patients", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "For descriptive analysis of toxicity/safety, summary tables will be presented showing the total number of patients reporting at least one specific event stratified by System Organ Class, Common terminology criteria for adverse events (CTCAE) term, CTCAE grade and causality.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "approx. 12 month"
            }
        ], 
        "overall_contact": {
            "email": "helge.schroeder@aio-studien-ggmbh.de", 
            "last_name": "Helge Schr\u00f6der, Dipl.- Biol.", 
            "phone": "+49 - 30 - 8145 344", 
            "phone_ext": "35"
        }, 
        "overall_official": {
            "affiliation": "NCT-Med. Onkologie", 
            "last_name": "Georg Martin Haag, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "OS will be defined as the time length between randomization and the date of death from any cause or the date of last follow-up in case of no documentation of death.", 
            "measure": "Overall Survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "approx. 12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128243"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS will be defined as the time length between the date of randomization and the date of first disease progression or death (whichever occurs first).", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }, 
            {
                "description": "Quality of life will be evaluated using the validated European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 questionnaire and the gastric module STO22.", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "approx. 12 month"
            }
        ], 
        "source": "AIO-Studien-gGmbH", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Taiho Pharmaceutical Co., Ltd.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Nordic Pharma SAS", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "AIO-Studien-gGmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}